FACULTY
Aparna Parikh, MD
Associate Professor of Medicine, Harvard Medical School
Director of the MGH Cancer Center’s Global Cancer Care Program
Director of Colorectal Medical Oncology
Medical Director Center for Young Adult Colorectal Cancer FASCO
Massachusetts General Hospital Cancer Center
Tucker Gosnell Center for Gastrointestinal Malignancies
Termeer Center for Targeted Therapies
Boston, MA
PROGRAM OVERVIEW
This enduring presentation is designed to assist members of multidisciplinary oncology care teams at VA hospitals, including oncologists, pathologists, and nurse practitioners, so that they may better understand and implement molecular diagnostic approaches and biomarker-driven testing strategies in their veteran patients with cancer. The program places special emphasis on the role of NTRK gene fusion and TRK fusion testing, the implications of TRK pathway aberrations in cancer pathogenesis, and clinical trial data surrounding TRK inhibitors.
TARGET AUDIENCE
This activity is intended for VA oncologists, VA pathologists, and nurse practitioners involved in the diagnosis and treatment of cancer patients.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the current and future methods to detect molecular alterations, including next-generation sequencing (NGS), and compare different molecular diagnostic approaches
- Implement appropriate biomarker-driven testing strategies in oncology practice
- Describe the role of NTRK gene fusion and the clinical implications of TRK-fusion testing in cancer treatment algorithms
- Evaluate the implications of TRK pathway aberrations in cancer pathogenesis and the efficacy and safety profiles of approved TRK inhibitors
- Demonstrate a multi-disciplinary approach to precision medicine by promoting collaboration among healthcare professionals in the integration of TRK inhibitors into treatment plans
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Aparna Parikh, MD | Consultant | Amgen, Eli Lilly, Mirati, Pfizer, Inivata, Biofidelity, Checkmate Pharmaceuticals, FMI, Guardant, AbbVie, Bayer, Delcath Systems, CVS, Value Analytics Lab, Seagen, SAGA Diagnostics, AstraZeneca, Scarce, Illumina, Taiho Oncology, Hookipa Pharma, Kahar Medical, Xilio Therapeutics, Sirtex, Takeda, Merck, MPM Capital and Science For America |
| Contracted research | UpToDate, PureTech Health, PMV Pharmaceuticals, Plexxikon, Takeda, Bristol Myers Squibb, Mirati Therapeutics, Novartis, Erasca, Genentech, Daiichi Sankyo, Syndax, Revolution Medicine, and Parthenon | |
| Fees for Non-CME/CE Services Received Directly from a Commercial Interest or its Agent* | Karkinos Healthcare, Up to Date | |
| Data and Safety Monitoring Committee | Roche Clinical Trials, Steering Committee for Exelixis | |
| Stock Options | C2i Genomics, Khora Therapeutics, XGenomes, Cadex, and Parithera |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Sunali Wadehra, MD, Medical Director for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 25, 2024
EXPIRATION DATE: November 25, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
